AIM
AST

Acrospire Investment Management’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Acrospire Investment Management’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-6,101
Closed -$28K – 2740
2016
Q4 		$28K Buy
+6,101
New +$25.2K 0.01% 1663

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Acrospire Investment Management's AST Position: Q1 2017 in Review

Acrospire Investment Management sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2017, closing a stake of 6,101 shares — an estimated $28K sold.

Acrospire Investment Management first reported a position in AST in Q4 2016 and held it in 1 quarter. The position peaked at $28K in Q4 2016. 66 funds tracked by Wall St. Rank hold AST as of Q1 2017.

  • Acrospire Investment Management reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 6,101 Asterias Biotherapeutics Inc. Series A shares in Q1 2017, an estimated $28K.
  • Acrospire Investment Management first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2016 and held it in 1 quarter.
  • Acrospire Investment Management's Asterias Biotherapeutics Inc. Series A position peaked at $28K in Q4 2016.
  • 66 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.